CERRITOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate at the following investor conferences:
Cowen Annual Health Care Conference
Date: March 4th, 2024
Presentation: 2:50pm Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer
Location: Boston, MA
Jefferies Value Based Healthcare Summit
Date: March 11th, 2024
Fireside Chat: 10:30am Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer
Location: Miami, FL
Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/. The online replay will be available for a limited time shortly following the call.
About The Oncology Institute, Inc.
Founded in 2007, The Oncology Institute, Inc. (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.32 |
Daily Change: | 0.05 18.84 |
Daily Volume: | 1,309,363 |
Market Cap: | US$23.880M |
November 13, 2024 November 11, 2024 September 30, 2024 August 13, 2024 May 14, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB